Predictive Value of First Trimester APRI Score and FIB-4 Index for Gestational Diabetes Mellitus
The European Research Journal · 2026-11-01 · 1302-1309
DOI: 10.18621/eurj.1261 ↗Abstract
Objective: Inflammation, liver injury, and subclinical fibrotic processes secondary to insulin resistance are thought to play an important role in gestational diabetes mellitus (GDM). This study aimed to evaluate the predictive value of the aspartate aminotransferase–platelet ratio index (APRI) and fibrosis-4 (FIB-4) index, which reflect inflammatory status and hepatic involvement, for the prediction of GDM. Methods: This retrospective cohort study evaluated 3305 singleton pregnant women who delivered at Bursa Yüksek İhtisas Training and Research Hospital between January 2020 and December 2024. Participants were stratified into 371 women diagnosed with GDM and 2934 normoglycemic controls. First-trimester laboratory parameters, APRI scores, and FIB4 indices were comparatively analyzed between the groups. Results: The median APRI score and FIB4 index were significantly higher in the GDM cohort than in controls (P < .001 and P = .03, respectively). An APRI score > 0.22 predicted GDM with 61.46% sensitivity and 66.02% specificity (area under the curve [AUC] = 0.667; P < .001). Conversely, a FIB4 index greater than >0.53 demonstrated 66.31% sensitivity and 41.00% specificity (AUC = 0.535; P = .03). Receiver operating characteristic curve comparison using the DeLong method demonstrated that the first-trimester APRI score had significantly superior discriminative performance for GDM compared with the FIB4 index (P < .001). APRI scores showed no significant associations with clinical variables, whereas FIB4 scores correlated weakly with maternal age and parity. Conclusions: Both first-trimester APRI and FIB4 scores are significantly associated with GDM, serving as noninvasive, cost-effective biomarkers for risk stratification. Notably, APRI demonstrates superior predictive performance compared with FIB4, highlighting its potential utility as a screening adjunct in early obstetric care.
EUVIMED